Trastuzumab deruxtecan in breast cancer
Source : https://pubmed.ncbi.nlm.nih.gov/38621469/
Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC) consisting of a humanised, anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibody covalently linked to a topoisomerase I inhibitor cytotoxic payload...
Trastuzumab deruxtecan (T-DXd) revolutionizes HER2-targeted therapy for metastatic breast cancer, demonstrating efficacy in both HER2-positive and HER2-low cancers, potentially altering treatment paradigms across various settings.
Screening for Breast Cancer: A Comparative Review of Guidelines
Source : https://pubmed.ncbi.nlm.nih.gov/38929759/
Breast cancer is the most common malignancy diagnosed in the female population worldwide and the leading cause of death among perimenopausal women. Screening is essential, since earlier detection in combination...
Consistent guidelines recommend mammography as the primary screening tool for average-risk women aged 40-74, with variations in screening frequency and cessation age based on individual health and life expectancy. Harmonizing international protocols can optimize breast cancer screening effectiveness and clinical guidance.
Public neoantigens in breast cancer immunotherapy (Review)
Source : https://pubmed.ncbi.nlm.nih.gov/38904202/
Among women globally, breast cancer is the most prevalent cancer and the leading cause of cancer‑related death. Interestingly, though genetic mutations contribute to the disease, <15% of women diagnosed with...
Public neoantigens offer promising avenues for immunotherapy in breast cancer, leveraging shared mutations to potentially broaden therapeutic benefits beyond individualized approaches, marking a significant advancement in cancer treatment strategies.
Platinum chemotherapy for early triple-negative breast cancer
Source : https://pubmed.ncbi.nlm.nih.gov/38492276/
Platinum-based chemotherapy using carboplatin in the adjuvant or neoadjuvant setting improves long-term outcomes of DFS and OS in early TNBC, with no evidence of differences by subgroup. This was at...
Platinum-based chemotherapy using carboplatin in the adjuvant or neoadjuvant setting improves long-term outcomes of DFS and OS in early TNBC.
Use of Antibody-Drug Conjugates in the Early Setting of Breast Cancer
Source : https://pubmed.ncbi.nlm.nih.gov/38894701/
Antibody-drug conjugates (ADCs) are anticancer agents with the capacity to selectively deliver their payloads to cancer cells. Antibody-drug conjugates consist of a monoclonal antibody backbone connected by a linker to...
Several ADCs targeting HER2, HER3, TROP2, or LIV1 are in clinical trials for early breast cancer. T-DM1, T-DXd, and SG are among the advanced-stage ADCs, while promising newcomers like ARX788 and TQB2102 show favorable results, advancing treatment options.